|
JNJ-78278343 Clinical Trials
3 actively recruiting trials across 2 locations
Also known as: KLK2-CD3, Pasritamig
Sarasota, Florida2 trials
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Florida Cancer Specialists
Phase 1
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Florida Cancer Specialists
Phase 1
Aurora, Colorado1 trial
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
University of Colorado Anschutz Medical Campus
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.